A Phase I, Multicenter, Open-Label, Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 when Administered Intravenously in Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
Phase of Trial: Phase I
Latest Information Update: 30 Jun 2014
At a glance
- Drugs VAY 736 (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Novartis
- 10 Oct 2013 Status changed from recruiting to discontinued, according to M.D. Anderson Cancer Center record.
- 10 Oct 2013 New source identified and integrated: M.D. Anderson Cancer Center record.
- 25 Oct 2012 New trial record